BioSyent Inc.
RX
Rank in Stocks
#18141
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops,... BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. BioSyent Inc. was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. The company was incorporated in 2006 and is headquartered in Mississauga, Canada.
Share Price
$12.68
Last synced: 2026-11-09
Market Cap
$143.35M
Change (1 day)
1.02%
Change (1 year)
63.94%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade BioSyent Inc. (RX)
Category
Healthcare
Operating Margin for BioSyent Inc. (RX)
Operating Margin as of November 2026 TTM: 23.21%
According to BioSyent Inc.'s latest financial reports, its current operating margin (TTM) is 23.21%. At the end of 2025 the company had an operating margin of 26.28%.
Operating Margin history for BioSyent Inc. from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 23.21% | -11.68% |
| 2025 | 26.28% | 5.16% |
| 2024 | 24.99% | 5.67% |
| 2023 | 23.65% | -5.40% |
| 2022 | 25.00% | -12.56% |
| 2021 | 28.59% | 26.95% |
| 2020 | 22.52% | -10.46% |
| 2019 | 25.15% | -20.31% |
| 2018 | 31.56% | -4.33% |
| 2017 | 32.99% | 2.77% |
| 2016 | 32.10% | -2.34% |
| 2015 | 32.87% | -5.65% |
| 2014 | 34.84% | 12.31% |
| 2013 | 31.02% | 11.38% |
| 2012 | 27.85% | 50.95% |
| 2011 | 18.45% | 585.87% |
| 2010 | 2.69% | -109.42% |
| 2009 | -28.57% | 3.03% |
| 2008 | -27.73% | 90.06% |
| 2007 | -14.59% | -161.93% |
| 2006 | 23.56% | -275.69% |
| 2005 | -13.41% | -69.50% |
| 2004 | -43.97% | -19.69% |
| 2003 | -54.75% | -33.14% |
| 2002 | -81.89% | 19.93% |
| 2001 | -68.28% | 77.67% |
| 2000 | -38.43% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 62.34% | -97.31% |
US
|
|
| 31.60% | -98.64% |
SE
|
|
| 30.13% | -98.70% |
FR
|
|
| 29.76% | -98.72% |
HK
|
|
| 30.46% | -98.69% |
IT
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about BioSyent Inc.'s operating margin
What is BioSyent Inc.'s operating margin?
BioSyent Inc.'s operating margin is 23.21%, as of Nov 2026.
What was BioSyent Inc.'s operating margin in 2025?
In 2025, BioSyent Inc.'s operating margin was 26.28%, compared with 24.99% in 2024.
How has BioSyent Inc.'s operating margin changed since 2020?
From 2020 to 2025, BioSyent Inc.'s operating margin was highest in 2021 (28.59%) and lowest in 2020 (22.52%).
How does BioSyent Inc.'s operating margin compare with similar companies?
BioSyent Inc.'s operating margin (23.21%) is lower than that of all 5 similar companies listed above. The highest among them is Royalty Pharma plc, with 62.34%.